424 related articles for article (PubMed ID: 17659355)
1. The evasive nature of drug efficacy: implications for drug discovery.
Galandrin S; Oligny-Longpré G; Bouvier M
Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
[TBL] [Abstract][Full Text] [Related]
2. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.
Bosier B; Hermans E
Trends Pharmacol Sci; 2007 Aug; 28(8):438-46. PubMed ID: 17629964
[TBL] [Abstract][Full Text] [Related]
3. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
Kenakin T
Trends Pharmacol Sci; 2007 Aug; 28(8):407-15. PubMed ID: 17629960
[TBL] [Abstract][Full Text] [Related]
4. Functional selectivity through protean and biased agonism: who steers the ship?
Kenakin T
Mol Pharmacol; 2007 Dec; 72(6):1393-401. PubMed ID: 17901198
[TBL] [Abstract][Full Text] [Related]
5. New concepts in drug discovery: collateral efficacy and permissive antagonism.
Kenakin T
Nat Rev Drug Discov; 2005 Nov; 4(11):919-27. PubMed ID: 16264435
[TBL] [Abstract][Full Text] [Related]
6. When simple agonism is not enough: emerging modalities of GPCR ligands.
Smith NJ; Bennett KA; Milligan G
Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
[TBL] [Abstract][Full Text] [Related]
7. Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling.
Piñeyro G
Cell Signal; 2009 Feb; 21(2):179-85. PubMed ID: 18790047
[TBL] [Abstract][Full Text] [Related]
8. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy.
Galandrin S; Bouvier M
Mol Pharmacol; 2006 Nov; 70(5):1575-84. PubMed ID: 16901982
[TBL] [Abstract][Full Text] [Related]
9. [G-protein-coupled receptors plasticity and signalling].
Galés C
Med Sci (Paris); 2012 Oct; 28(10):883-5. PubMed ID: 23067421
[TBL] [Abstract][Full Text] [Related]
10. Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities.
Seifert R; Dove S
Mol Pharmacol; 2009 Jan; 75(1):13-8. PubMed ID: 19001067
[TBL] [Abstract][Full Text] [Related]
11. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
Kenakin T
Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
[TBL] [Abstract][Full Text] [Related]
12. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
13. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors.
Costa T; Cotecchia S
Trends Pharmacol Sci; 2005 Dec; 26(12):618-24. PubMed ID: 16260046
[TBL] [Abstract][Full Text] [Related]
14. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.
Leach K; Sexton PM; Christopoulos A
Trends Pharmacol Sci; 2007 Aug; 28(8):382-9. PubMed ID: 17629965
[TBL] [Abstract][Full Text] [Related]
15. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?
Greasley PJ; Clapham JC
Eur J Pharmacol; 2006 Dec; 553(1-3):1-9. PubMed ID: 17081515
[TBL] [Abstract][Full Text] [Related]
16. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant?
Parra S; Bond RA
Curr Opin Pharmacol; 2007 Apr; 7(2):146-50. PubMed ID: 17284360
[TBL] [Abstract][Full Text] [Related]
17. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling.
Luttrell LM; Kenakin TP
Methods Mol Biol; 2011; 756():3-35. PubMed ID: 21870218
[TBL] [Abstract][Full Text] [Related]
18. Innovation and greater probability of success in drug discovery and development -- from target to biomarkers.
Kola I; Hazuda D
Curr Opin Biotechnol; 2005 Dec; 16(6):644-6. PubMed ID: 16263257
[No Abstract] [Full Text] [Related]
19. Computational chemistry approaches to drug discovery in signal transduction.
Fischer PM
Biotechnol J; 2008 Apr; 3(4):452-70. PubMed ID: 18412174
[TBL] [Abstract][Full Text] [Related]
20. Allosteric properties of G protein-coupled receptor oligomers.
Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
